EGFR and non-small cell lung carcinoma: Afterward, the CTONG1104/ADJUVANT was a phase three trial evaluating the efficacy of adjuvant gefitinib versus standard platinum-based chemotherapy in resected stage II–IIIA EGFR mutant NSCLC.